The potential for targeting the STAT3 pathway as a novel therapy for melanoma

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

(2013) A. Quintas-Cardama et al.   CLINICAL CANCER RESEARCH

Immunotherapy of cancer in 2012

(2012) John M. Kirkwood et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines

(2012) Matthew A. Bill et al.   PLoS One

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

(2012) X. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects

(2010) M. Kujawski et al.   CANCER RESEARCH

Inhibition of p-STAT3 Enhances IFN-  Efficacy against Metastatic Melanoma in a Murine Model

(2010) L. Y. Kong et al.   CLINICAL CANCER RESEARCH

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

(2010) Matthew A Bill et al.   Molecular Cancer

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

(2009) Marcin Kortylewski et al.   NATURE BIOTECHNOLOGY

Targeting STAT3 in cancer: how successful are we?

(2008) Peibin Yue et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS